Known targets — ChEMBL curated mechanism
ACHEADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3APH1AAPH1BCHRM2CHRM3EZH2GRIN2AHTR1AHTR1BHTR1DHTR1FHTR3ANCSTNP2RY12PSEN1PSEN2PSENENSIGMAR1SLC6A2SLC6A3SLC6A4
The experimentally established mechanism targets of Bromide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 4/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 1.00 |
| ▸ | LMNA | P02545 | 2/20 | 1.00 |
| ▸ | HPGD | P15428 | 2/20 | 1.00 |
| ▸ | PMP22 | Q01453 | 2/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 2/20 | 1.00 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 1.00 |
| ▸ | GMNN | O75496 | 1/20 | 1.00 |
| ▸ | G6PD | P11413 | 1/20 | 1.00 |
| ▸ | RECQL | P46063 | 1/20 | 1.00 |
| ▸ | DRD2 | P14416 | 6/20 | 0.98 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.98 |
| ▸ | RGS12 | O14924 | 2/20 | 0.98 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.98 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.98 |
| ▸ | THPO | P40225 | 2/20 | 0.98 |
| ▸ | MTOR | P42345 | 2/20 | 0.98 |
| ▸ | GNAI1 | P63096 | 2/20 | 0.98 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.98 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Bromide SCHEMBL4923286 | 1.00 | MAPT (1.00) | MAPTALDH1A1KDM4ELMNAHPGD | |
| Bromide SCHEMBL31027963 | 1.00 | MAPT (1.00) | MAPTALDH1A1KDM4ELMNAHPGD | |
| SCHEMBL107293 | 0.99 | DRD2 (1.00) | MAPTALDH1A1KDM4ELMNAHPGD | |
| SCHEMBL8344207 | 0.99 | DRD2 (1.00) | MAPTALDH1A1KDM4ELMNAHPGD | |
| SCHEMBL140170 | 0.99 | DRD2 (1.00) | MAPTALDH1A1KDM4ELMNAHPGD | |
| SCHEMBL29602749 | 0.99 | DRD2 (1.00) | MAPTALDH1A1KDM4ELMNAHPGD | |
| SCHEMBL12877906 | 0.88 | DRD2 (0.80) | MAPTALDH1A1KDM4ELMNAHPGD | |
| Bromide SCHEMBL1325230 | 0.86 | MAPT (1.00) | MAPTALDH1A1KDM4ELMNAHPGD | |
| Bromide SCHEMBL1325232 | 0.86 | MAPT (1.00) | MAPTALDH1A1KDM4ELMNAHPGD | |
| SCHEMBL8097389 | 0.85 | DRD1 (0.77) | MAPTALDH1A1KDM4ELMNAHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220071955-A1 | Methods of Treatment, Prevention and Diagnosis | THE WALTER AND ELIZA HALL INSTITUTE OF MEDICAL RESEARCH (AU) | 2022-03-10 | — | — | US | claimed |
| EP-3873461-A1 | METHODS OF TREATMENT, PREVENTION AND DIAGNOSIS | The Walter and Eliza Hall Institute of Medical Research (AU) | 2021-09-08 | — | — | EP | claimed |
| US-20220071955-A1 | Methods of Treatment, Prevention and Diagnosis | THE WALTER AND ELIZA HALL INSTITUTE OF MEDICAL RESEARCH (AU) | 2022-03-10 | — | — | US | disclosed |
| EP-3873461-A1 | METHODS OF TREATMENT, PREVENTION AND DIAGNOSIS | The Walter and Eliza Hall Institute of Medical Research (AU) | 2021-09-08 | — | — | EP | disclosed |
| US-20080096909-A1 | APOMORPHINE INHIBITORS OF AMYLOID-BETA (ABETA) FIBRIL FORMATION AND THEIR USE IN AMYLOIDOSIS BASED DISEASE | CYTOKINE PHARMASCIENCES, INC. (US) | 2008-04-24 | — | — | US | disclosed |
| US-20030187011-A1 | Apomorphine inhibitors of amyloid-beta (Abeta) fibril formation and their use in amyloidosis based disease | CYTOKINE PHARMASCIENCES, INC. | 2003-10-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220071955-A1 | Methods of Treatment, Prevention and Diagnosis | TARDBP, GRN, FUS | MAPT 12/4885ALDH1A1 2860/4885KDM4E 3195/4885 |
| US-20080096909-A1 | APOMORPHINE INHIBITORS OF AMYLOID-BETA (ABETA) FIBRIL FORMATION AND THEIR USE IN AMYLOIDOSIS BASED DISEASE | APP, PNMT, APOB | MAPT 4/4885ALDH1A1 1645/4885KDM4E 2846/4885 |
| US-20030187011-A1 | Apomorphine inhibitors of amyloid-beta (Abeta) fibril formation and their use in amyloidosis based disease | PNMT, APP, MAPT | MAPT 3/4885ALDH1A1 1730/4885KDM4E 3022/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.